Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]
| Products Name (INN Index) | Pre-Made Anatumomab Mafenatox biosimilar, Fusion Protein: Anatumomab-Anti-TAG-72 therapeutic antibody fused with Staphylococcus aureus enterotoxin A |
|---|---|
| INN Name | anatumomab mafenatox |
| Target | tag-72 |
| Format | Fusion Protein |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | Fab – G1 – kappa |
| VD LC | Fab – G1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TAG-72 |
| Package |
